{"schema_version":"secwatch.filing_event.v1","accession":"0000313616-25-000155","form_type":"8-K","ticker":"DHR","cik":"0000313616","company_name":"DANAHER CORP /DE/","filed_at":"2025-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.025502+00:00","generated_at":"2026-05-18T02:44:14.501781+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Danaher names Matthew Gugino as CFO effective Feb 28, 2026; McGrew to remain EVP","bullets":["Matthew M. McGrew to step down as CFO effective Feb 28, 2026, continue as Executive Vice President.","Matthew E. Gugino, currently Group CFO of Life Sciences Innovations, appointed CFO effective Feb 28, 2026.","Gugino's base salary increases to $700k now, $825k upon CFO start; equity target $4.2M in 2026.","McGrew's 2026 compensation: base salary $700k, target bonus 125%, equity $2.5M.","Gugino joined Danaher in 2013; previously at Barclays, Morgan Stanley, KPMG."],"urls":{"canonical":"https://secwatch.observer/filing/0000313616-25-000155","json":"https://secwatch.observer/filing/0000313616-25-000155.json","markdown":"https://secwatch.observer/filing/0000313616-25-000155.md","text":"https://secwatch.observer/filing/0000313616-25-000155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/313616/000031361625000155/0000313616-25-000155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/313616/000031361625000155/dhr-20250721.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T02:44:14.501781+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}